XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.3
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenues Based on Patient Location (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Revenue $ 581,329 $ 505,344 $ 1,773,019 $ 1,558,501
ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 13,812 29,046 88,533 90,755
Product        
Disaggregation of Revenue [Line Items]        
Revenue 568,266 493,348 1,739,390 1,516,533
Marketed by Company | Products excluding ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 554,454 464,302 1,650,857 1,425,778
Marketed by Company | Products excluding ALDURAZYME | United States        
Disaggregation of Revenue [Line Items]        
Revenue 194,745 176,552 553,184 497,205
Marketed by Company | Products excluding ALDURAZYME | Europe        
Disaggregation of Revenue [Line Items]        
Revenue 168,784 162,583 512,910 480,645
Marketed by Company | Products excluding ALDURAZYME | Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 81,524 60,791 224,716 213,246
Marketed by Company | Products excluding ALDURAZYME | Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 109,401 64,376 360,047 234,682
Marketed by Sanofi | ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue $ 13,812 $ 29,046 $ 88,533 $ 90,755